With training and planning, self-injecting your rheumatoid arthritis medication may be easier than you think.

The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript February 5, 2026 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $0.22 EPS, expectations ...

Raises 2026 Financial Guidance Ranges: – Increases Total Revenue to $1,710 – $1,810 million, YoY Growth of 23% to 30%2 – ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

The full results of a phase 3 clinical trial showed that patients with moderate-to-severe active systemic lupus erythematosus (SLE) who received standard treatment achieved greater reductions in ...

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version of lupus treatment Saphnelo. | AstraZeneca will have to negotiate what ...

The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

Doctors say they have achieved the previously impossible - restoring sight and preventing blindness in people with a rare but dangerous eye conditon called hypotony. Moorfields hospital in London is ...